Roselabs Peer Comparison

BSE: 535503

₹7.70

₹0.36 (4.90%)

As on 23-Dec-2015IST

Market cap

₹8 Cr

Revenue (TTM)

₹6 Cr

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Edit

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	8	31,863	30,485	28,611	27,284
Revenue (₹ Cr)	6	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-0.35	414.00	288.22	-371.81	387.35
Net Margin (%)	-6.11	11.23	14.79	-3.93	26.01
RoE (%)	-2.69	8.38	29.77	-3.85	25.18
Price to Earnings	--	77.90	105.77	--	70.64
Price-To-Book	0.79	6.33	22.71	3.57	15.78

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	33.11	4,481.54	39.21	--	111.75
Total Income	33.11	4,548.09	39.54	--	111.77
Total Expenditure	33.15	3,772.14	28.05	--	103.45
EBITDA	-0.04	709.40	11.16	--	8.29
Depreciation	0.23	145.40	5.18	--	0.72
EBIT	-0.27	564.00	5.98	--	7.58
Interest	0.52	55.21	2.37	--	1.59
Other Income	0.00	66.55	0.33	--	0.02
Exceptional Items	--	49.83	--	--	--
Profit before Tax	-0.79	575.34	3.94	--	6.01
Provision for Tax	-0.02	162.65	1.27	--	1.91
Profit after Tax	-0.78	412.69	2.67	--	4.10

Liabilities (₹ Cr)

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	11.95	3,715.35	47.49	--	14.83
Minority Interest	--	143.95	--	--	--
Non-Current Liabilities	1.32	1,872.46	11.98	--	6.27
Current Liabilities	20.49	1,772.97	24.42	--	37.80
Total Liabilities	33.76	7,504.73	83.90	--	59.21

Assets (₹ Cr)

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	8.40	3,983.17	53.02	--	11.26
Current Assets	25.36	3,521.56	30.88	--	47.65
Total Assets	33.76	7,504.73	83.90	--	59.21
Total Debt*	10.75	2,010.07	26.03	--	22.92
Net Current Assets	4.87	1,748.59	6.46	--	9.84
Contingent Liabilities	--	295.45	4.70	--	--

Cashflow (₹ Cr)

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	0.06	354.96	10.55	--	-3.88
Cash Flow from Investing Activities	-0.36	-206.63	-5.46	--	-4.44
Cash from Financing Activities	-0.43	-75.65	-10.21	--	8.61
Net Cash Inflow / Outflow	-0.73	72.68	0.34	--	0.29

Ratios

Profitability Ratios

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-1.15	11.25	9.04	--	25.03
ROE (%)	-7.68	12.49	9.82	--	31.99
ROA (%)	-1.69	5.84	3.33	--	8.42
EBIT Margin (%)	-0.11	17.31	29.29	--	7.44
Net Margin (%)	-2.34	9.07	6.75	--	3.66
Cash Profit Margin (%)	-1.64	12.43	19.93	--	4.31

Growth Ratios

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-62.64	-7.22	-5.70	--	46.82
EBIT Growth (%)	-102.32	-27.08	-2.08	--	24.42
Net Profit Growth (%)	-908.61	-51.03	-40.70	--	42.98
EPS Growth (%)	-908.61	-42.48	-40.70	--	42.98
Book Value Growth (%)	-7.40	4.11	10.33	--	37.67

Valuation Ratios

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	46.73	0.00	--	0.00
Price / Book Value	1.04	6.09	0.00	--	0.00
Dividend Yield (%)	0.00	1.07	--	--	--
EV/EBITDA	-548.22	27.84	4.00	--	2.87
Market Cap (₹ Cr)	10.06	20,529.92	0.00	--	0.00

Solvency Ratios

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	1.11	0.55	0.55	--	1.55
Short term debt to equity ratio	0.82	0.09	0.27	--	0.97
Current Ratio	1.24	1.99	1.26	--	1.26
Quick Ratio	1.15	1.41	1.22	--	0.89
Interest Coverage	-0.51	11.42	2.66	--	4.78

Operating Efficiency Ratios

	Roselabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	49.65	16.54	42.87	--	21.80
Asset Turnover	0.72	0.64	0.49	--	2.30
Receivable days	292.59	49.71	143.12	--	61.92
Inventory Days	17.44	81.88	10.03	--	41.26
Payable days	234.09	136.23	216.06	--	94.00
Cash Conversion Cycle	75.95	-4.64	-62.91	--	9.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly